EP3116996A4 - Treatment of resistant lesions - Google Patents

Treatment of resistant lesions Download PDF

Info

Publication number
EP3116996A4
EP3116996A4 EP15760904.1A EP15760904A EP3116996A4 EP 3116996 A4 EP3116996 A4 EP 3116996A4 EP 15760904 A EP15760904 A EP 15760904A EP 3116996 A4 EP3116996 A4 EP 3116996A4
Authority
EP
European Patent Office
Prior art keywords
treatment
resistant lesions
lesions
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15760904.1A
Other languages
German (de)
French (fr)
Other versions
EP3116996A2 (en
Inventor
David EISENBUD
Anthony Phillips
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocunexus Therapeutics Inc
Original Assignee
Ocunexus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocunexus Therapeutics Inc filed Critical Ocunexus Therapeutics Inc
Publication of EP3116996A2 publication Critical patent/EP3116996A2/en
Publication of EP3116996A4 publication Critical patent/EP3116996A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15760904.1A 2014-03-14 2015-03-16 Treatment of resistant lesions Withdrawn EP3116996A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953608P 2014-03-14 2014-03-14
US201461953604P 2014-03-14 2014-03-14
PCT/US2015/020786 WO2015139047A2 (en) 2014-03-14 2015-03-16 Treatment of resistant lesions

Publications (2)

Publication Number Publication Date
EP3116996A2 EP3116996A2 (en) 2017-01-18
EP3116996A4 true EP3116996A4 (en) 2018-01-10

Family

ID=54072608

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15760904.1A Withdrawn EP3116996A4 (en) 2014-03-14 2015-03-16 Treatment of resistant lesions

Country Status (3)

Country Link
EP (1) EP3116996A4 (en)
CA (1) CA2941140A1 (en)
WO (1) WO2015139047A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073479A2 (en) * 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
WO2009075881A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2014145342A2 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Improved wound healing compositions and treatments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507855A (en) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
US8821933B2 (en) * 2010-11-01 2014-09-02 Nanoderm Sciences, Inc. Polymers and hydrogels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073479A2 (en) * 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
WO2009075881A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2014145342A2 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Improved wound healing compositions and treatments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARIADNA MENDOZA-NARANJO ET AL: "Overexpression of the gap junction protein Cx43 as found in diabetic foot ulcers can retard fibroblast migration", CELL BIOLOGY INTERNATIONAL., vol. 36, no. 7, 8 June 2012 (2012-06-08), GB, pages 661 - 667, XP055402070, ISSN: 1065-6995, DOI: 10.1042/CBI20110628 *
JOHANNA M BRANDNER ET AL: "See related Commentary on page ix Connexins 26, 30, and 43: Differences Among Spontaneous, Chronic, and Accelerated Human Wound Healing", 1 May 2004 (2004-05-01), XP055402063, Retrieved from the Internet <URL:http://ac.els-cdn.com/S0022202X15308010/1-s2.0-S0022202X15308010-main.pdf?_tid=93f36308-8cba-11e7-9b03-00000aab0f26&acdnat=1504012043_813c67923de0c385013b5614ac11fb7b> [retrieved on 20170829] *
MORI RYOICHI ET AL: "Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 119, no. 24, 1 December 2006 (2006-12-01), pages 5193 - 5203, XP002529576, ISSN: 0021-9533, DOI: 10.1242/JCS.03320 *
QIU C ET AL: "Targeting Connexin43 Expression Accelerates the Rate of Wound Repair", CURRENT BIO, CURRENT SCIENCE, GB, vol. 13, no. 19, 30 September 2003 (2003-09-30), pages 1697 - 1703, XP004545249, ISSN: 0960-9822, DOI: 10.1016/J.CUB.2003.09.007 *
WANG CHINHUI MARY ET AL: "Abnormal connexin expression underlies delayed wound healing in diabetic skin", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 56, no. 11, 1 November 2007 (2007-11-01), pages 2809 - 2817, XP002529575, ISSN: 0012-1797, [retrieved on 20070823], DOI: 10.2337/DB07-0613 *

Also Published As

Publication number Publication date
EP3116996A2 (en) 2017-01-18
WO2015139047A3 (en) 2015-12-10
CA2941140A1 (en) 2015-09-17
WO2015139047A2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
EP3212233A4 (en) Combination therapy for treatment of disease
EP3072436A4 (en) Endoscope
EP3134436A4 (en) Treatment of h-ras-driven tumors
EP3078318A4 (en) Endoscope
EP3097843A4 (en) Endoscope
EP3047788A4 (en) Endoscope
EP3157565A4 (en) Treatment of polybacterials infections
EP3050488A4 (en) Endoscope
EP3183240A4 (en) Treatment of joint conditions
EP3104880A4 (en) Improved methods for the treatment of vascularizing cancers
EP3092940A4 (en) Endoscope
EP3106097A4 (en) Treatment instrument
EP3205253A4 (en) Endoscope
EP3175768A4 (en) Endoscope
EP3189333A4 (en) Diagnosis of cancer
EP3145931A4 (en) Treatment of autoimmune disease
EP3231347A4 (en) Endoscope
EP3138467A4 (en) Endoscope
EP3158912A4 (en) Endoscope
EP3125937A4 (en) Treatment of gastric cancer
EP3106112A4 (en) Treatment instrument
EP3130274A4 (en) Endoscope
EP3096752A4 (en) Treatment of neoplasia
EP3106119A4 (en) Treatment instrument
GB201408297D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20170901BHEP

Ipc: A61K 31/7088 20060101ALI20170901BHEP

Ipc: C07H 21/04 20060101ALI20170901BHEP

Ipc: C12N 15/11 20060101AFI20170901BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20171208

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20171204BHEP

Ipc: A61K 31/7088 20060101ALI20171204BHEP

Ipc: C07H 21/04 20060101ALI20171204BHEP

Ipc: C12N 15/11 20060101AFI20171204BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180714